Among 381 patients who had received paclitaxel-containing regimens, higher E2F2 expression levels were still significantly associated with poorer PFS and OS values (Fig. 5H), strongly suggesting that the E2F2 expression in ovarian cancer is related to paclitaxel resistance. Here, E2F2 is linked to ovarian carcinoma.